Literature DB >> 16946310

Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs.

R Bell1, R Neiger, Y McGrotty, I K Ramsey.   

Abstract

The effects of trilostane, a 3beta-hydroxysteroid dehydrogenase inhibitor on basal cortisol concentrations and the results of ACTH stimulation tests in dogs with pituitary-dependent hyperadrenocorticism were investigated. In eight of nine dogs trilostane suppressed the concentration of cortisol below the lower limit of the reference range (<50 nmol/l) for a mean (sd) of 3.5 (2.3) hours during the day, but for no longer than 13 hours. In another 10 dogs, there was a clear difference between the post ACTH cortisol concentrations observed four and 24 hours after the administration of trilostane. Furthermore, in the six dogs whose clinical signs were poorly controlled the post-ACTH concentrations observed four and 24 hours after the administration of trilostane were always higher than the equivalent cortisol concentrations in the four dogs whose clinical signs were controlled. A short duration of drug action may be responsible for the failure of some dogs to respond adequately to once daily trilostane administration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946310     DOI: 10.1136/vr.159.9.277

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  11 in total

1.  The influence of trilostane on steroid hormone metabolism in canine adrenal glands and corpora lutea-an in vitro study.

Authors:  C Ouschan; M Lepschy; F Zeugswetter; E Möstl
Journal:  Vet Res Commun       Date:  2011-11-25       Impact factor: 2.459

Review 2.  Update on the use of trilostane in dogs.

Authors:  Julie Lemetayer; Shauna Blois
Journal:  Can Vet J       Date:  2018-04       Impact factor: 1.008

3.  Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.

Authors:  C M Bonadio; E C Feldman; T A Cohen; P H Kass
Journal:  J Vet Intern Med       Date:  2014-05-26       Impact factor: 3.333

4.  Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane.

Authors:  J N Midence; K J Drobatz; R S Hess
Journal:  J Vet Intern Med       Date:  2015-09-16       Impact factor: 3.333

5.  Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Rion Uchiyama; Hidekazu Koyama
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

6.  Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.

Authors:  L Macfarlane; T Parkin; I Ramsey
Journal:  Vet Rec       Date:  2016-11-01       Impact factor: 2.695

7.  Cushing's syndrome-an epidemiological study based on a canine population of 21,281 dogs.

Authors:  Gaia Carotenuto; Eleonora Malerba; Costanza Dolfini; Francesca Brugnoli; Pasquale Giannuzzi; Giovanni Semprini; Paolo Tosolini; Federico Fracassi
Journal:  Open Vet J       Date:  2019-02-15

8.  Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Yumi Nakamura; Hidekazu Koyama
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

9.  Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  C Griebsch; C Lehnert; G J Williams; K Failing; R Neiger
Journal:  J Vet Intern Med       Date:  2013-12-16       Impact factor: 3.333

10.  Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  Carolina Arenas Bermejo; Dolores Pérez Alenza; Paula García San José; Lidia Llauet; Laura Pérez-López; Carlos Melián; Edward C Feldman
Journal:  J Vet Intern Med       Date:  2020-06-13       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.